Market Overview:
The global cancer supportive care drugs market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, rising awareness about cancer supportive care drugs, and the launch of new products. Based on type, the global cancer supportive care drugs market is segmented into G-CSFs (granulocyte-colony stimulating factors), ESAs (erythropoiesis stimulating agents), anti-emetics, bisphosphonates, opioids, and NSAIDs. The G-CSF segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 8% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to rising awareness about these drugs and their benefits among patients with cancer and healthcare professionals alike. Based on application, the global cancer supportive care drugs market is divided into chemotherapy therapy and radiation therapy segments.
Product Definition:
Cancer supportive care drugs are medications that are used to improve the quality of life for people with cancer. They can help manage symptoms such as pain, nausea, vomiting, and fatigue.
G-CSFs (Granulocyte-colony Stimulating Factors):
Granulocyte-colony stimulating factors (G-CSF) are a group of proteins that support granulocyte migration and proliferation during the treatment of chronic inflammatory diseases and cancer. G-CSF is widely used in the treatment of acute myeloid leukemia, which is one of the most common types of blood cancer.
ESAs (Erythropoiesis Stimulating Agents):
An ESAs is a group of medications used to increase the red blood cell count. These agents are used in cancer supportive care along with chemotherapy and radiation therapy. Cancer supportive care includes treatment of cancer-related anemia, which includes administration of drugs such as epoetin alfa (Epogen), aranesp, and methotrexate (Rheumatrex).
Application Insights:
The chemotherapy therapy segment dominated the global cancer supportive care drugs market in 2017. Chemotherapy is one of the most effective treatment methods for various cancers, such as lung, breast and colorectal cancer. The growing prevalence of chronic diseases caused by pollution and other environmental factors has led to an increase in demand for high-quality healthcare services across the globe. This trend is expected to drive growth over the forecast period.
Radiation therapy is used as a primary treatment method for some types of cancers, such as prostate cancer and skin tumor tumors (melanoma). Increasing R&D activities pertaining to radiation oncology is anticipated to boost market growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of cancer supportive care drugs and increased R&D investments by various companies. In addition, favorable reimbursement policies for oncology treatments in this region are also expected to boost revenue growth during the forecast period. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing healthcare expenditure levels, rising patient awareness about available treatment options, and government initiatives for improving healthcare infrastructure in emerging countries such as China & India & South Korea etcetera. Moreover, growing medical tourism industry due to low cost treatment is also anticipated fuel demand during future years (8).
Moreover, with an increase in disposable income levels coupled with economic development will lead towards an increase adoption rate of novel therapeutics resulting into higher revenue generation from this region over next eight years (9).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global cancer supportive care drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 609,640 people will die from this disease. This high incidence rate of cancer is expected to drive demand for various types of cancer supportive care drugs over the forecast period.
- Rising awareness about available treatments: There has been a rise in awareness about available treatments for different types of cancers among patients and healthcare professionals alike over recent years due to increasing research and development activities in this field. This is expected to result in an increase in demand for various types of cancer supportive care drugs over the forecast period as well as boost revenue growth prospects for players operating in this market space during that time frame too..
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Supportive Care Drugs Market Research Report
By Type
G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Anti-emetics, Bisphosphonates, Opioids, NSAIDs
By Application
Chemotherapy Therapy, Radiation Therapy
By Companies
Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Supportive Care Drugs Market Report Segments:
The global Cancer Supportive Care Drugs market is segmented on the basis of:
Types
G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), Anti-emetics, Bisphosphonates, Opioids, NSAIDs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chemotherapy Therapy, Radiation Therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Johnson & Johnson
- Merck
- Roche
- Helsinn Healthcare
- Heron Pharma
- Tesaro
- ...
Highlights of The Cancer Supportive Care Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- G-CSFs (Granulocyte-colony Stimulating Factors)
- ESAs (Erythropoiesis Stimulating Agents)
- Anti-emetics
- Bisphosphonates
- Opioids
- NSAIDs
- By Application:
- Chemotherapy Therapy
- Radiation Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Supportive Care Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer supportive care drugs are medications that help to improve the quality of life for people with cancer. These drugs can help to reduce pain, inflammation, and swelling; increase appetite and energy levels; and improve sleep.
Some of the major players in the cancer supportive care drugs market are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, Tesaro.
The cancer supportive care drugs market is expected to register a CAGR of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Supportive Care Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cancer Supportive Care Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cancer Supportive Care Drugs Market - Supply Chain
4.5. Global Cancer Supportive Care Drugs Market Forecast
4.5.1. Cancer Supportive Care Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cancer Supportive Care Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Cancer Supportive Care Drugs Market Absolute $ Opportunity
5. Global Cancer Supportive Care Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
5.3.1. G-CSFs (Granulocyte-colony Stimulating Factors)
5.3.2. ESAs (Erythropoiesis Stimulating Agents)
5.3.3. Anti-emetics
5.3.4. Bisphosphonates
5.3.5. Opioids
5.3.6. NSAIDs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Cancer Supportive Care Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
6.3.1. Chemotherapy Therapy
6.3.2. Radiation Therapy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Cancer Supportive Care Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Cancer Supportive Care Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Cancer Supportive Care Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Cancer Supportive Care Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Cancer Supportive Care Drugs Demand Share Forecast, 2019-2029
9. North America Cancer Supportive Care Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Cancer Supportive Care Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
9.4.1. Chemotherapy Therapy
9.4.2. Radiation Therapy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
9.7.1. G-CSFs (Granulocyte-colony Stimulating Factors)
9.7.2. ESAs (Erythropoiesis Stimulating Agents)
9.7.3. Anti-emetics
9.7.4. Bisphosphonates
9.7.5. Opioids
9.7.6. NSAIDs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Cancer Supportive Care Drugs Demand Share Forecast, 2019-2029
10. Latin America Cancer Supportive Care Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Cancer Supportive Care Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
10.4.1. Chemotherapy Therapy
10.4.2. Radiation Therapy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
10.7.1. G-CSFs (Granulocyte-colony Stimulating Factors)
10.7.2. ESAs (Erythropoiesis Stimulating Agents)
10.7.3. Anti-emetics
10.7.4. Bisphosphonates
10.7.5. Opioids
10.7.6. NSAIDs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Cancer Supportive Care Drugs Demand Share Forecast, 2019-2029
11. Europe Cancer Supportive Care Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Cancer Supportive Care Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
11.4.1. Chemotherapy Therapy
11.4.2. Radiation Therapy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
11.7.1. G-CSFs (Granulocyte-colony Stimulating Factors)
11.7.2. ESAs (Erythropoiesis timulating Agents)
11.7.3. Anti-emetics
11.7.4. Bisphosphonates
11.7.5. Opioids
11.7.6. NSAIDs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Cancer Supportive Care Drugs Demand Share, 2019-2029
12. Asia Pacific Cancer Supportive Care Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Cancer Supportive Care Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
12.4.1. Chemotherapy Therapy
12.4.2. Radiation Therapy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
12.7.1. G-CSFs (Granulocyte-colony Stimulating Factors)
12.7.2. ESAs (Erythropoiesis Stimulating Agents)
12.7.3. Anti-emetics
12.7.4. Bisphosphonates
12.7.5. Opioids
12.7.6. NSAIDs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Cancer Supportive Care Drugs Demand Share, 2019-2029
13. Middle East & Africa Cancer Supportive Care Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Cancer Supportive Care Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Cancer Supportive Care Drugs Market Size and Volume Forecast by Application
13.4.1. Chemotherapy Therapy
13.4.2. Radiation Therapy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Cancer Supportive Care Drugs Market Size and Volume Forecast by Type
13.7.1. G-CSFs (Granulocyte-colony Stimulating Factors)
13.7.2. ESAs (Erythropoiesis Stimulating Agents)
13.7.3. Anti-emetics
13.7.4. Bisphosphonates
13.7.5. Opioids
13.7.6. NSAIDs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Cancer Supportive Care Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Cancer Supportive Care Drugs Market: Market Share Analysis
14.2. Cancer Supportive Care Drugs Distributors and Customers
14.3. Cancer Supportive Care Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Johnson & Johnson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Helsinn Healthcare
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Heron Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Tesaro
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. ...
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
